RxDoctor Payments Data

Peter Carson

Washington, DCNPI 1588755227

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $672,838 of the $734,227 with a category attached, or 91.6%. Boehringer Ingelheim International GmbH accounts for 69.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $417,591 and has fallen 95.8% since, to $17,334 in 2025.

$734,227in general payments, 2019–2025

Across 319 payments — averaging $2301.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$507K
  • AbbVie$87K
  • Impulse Dynamics (USA) Inc.$68K
  • Livanova USA, Inc.$63K
  • Merck$7K
  • Amgen$1K
  • plus $1K from 4 others
$68,296in research payments, 2019–2025

Across 32 payments — averaging $2134.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$28K
  • AbbVie$17K
  • Merck$17K
  • Novartis$4K
  • Currax Pharmaceuticals LLC$3K

What the payments were for

  • Consulting fees$672,83892%
  • Speaking & faculty fees$7,9101%
  • Travel & lodging$50,6527%
  • Food & beverage$2,8270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →